MedTrace Logo

Rocuronium vs Cis-atracurium: Do Rocuronium Still 'ROCKS' In Coronary Artery Bypass Grafting

NCT06102915 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 289

Last updated 2023-11-28

No results posted yet for this study

Summary

The current trend in most cardiac surgeries was to use rocuronium as it provides faster recovery in train-of-four ratio compared to other aminosteroid non-depolarising neuromuscular blocker. However, as most cardiac centres' standard of care does not perform any neuromuscular monitoring nor antagonism of neuromuscular blockade effect, residual neuromuscular blockade could potentially be the key to delayed extubation. As such, Cis-atracurium's organ-independent Hofmann elimination could be in favour.

Conditions

  • Neuromuscular Blockade
  • Postoperative Pulmonary Atelectasis
  • Postoperative Pulmonary Complication
  • Coronary Artery Disease
  • Coronary Artery Bypass Grafting
  • Hypothermic Cardiopulmonary Bypass

Interventions

DRUG

Rocuronium Bromide 10 MG/ML

Comparative

DRUG

Nimbex 10 MG in 5 ML Injection

Comparative

Sponsors & Collaborators

  • Institut Jantung Negara

    lead OTHER

Principal Investigators

  • SONG LIN LOW, MBBS · IJN

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2023-11-23
Completion
2023-11-23

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06102915 on ClinicalTrials.gov